Pharmaceuticals, Biotechnology and Life Sciences
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) have entered into a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks.
Innate Pharma and Bristol-Myers Squibb have modified the clinical trial protocol for its ongoing Phase I/II trial evaluating the safety and tolerability of lirilumab in combination with Opdivo in patients with advanced refractory solid tumors.
Bristol-Myers Squibb has appointed Dr. Thomas J. Lynch, Jr. executive vice president and chief scientific officer, effective March 16, 2017.
Exelixis and Bristol-Myers Squibb have entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab).
Botswana will be a centert for southern and east Africa for hematology-oncology treatment, as it will get a new $100…
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
Bristol-Myers Squib on Thursday posted fourth quarter net earnings of $1.1 billion, driven ly by increased sales of Opdivo and Eliquis.
After Bristol-Myers Squibb (Bristol) said on Friday that it won’t ask FDA for faster approval of Opdivo/Yervoy combination for lung cancer, it agreed today with Ono Pharmaceutical to settle all patent-infringement charges related to Merck’s PD-1 antibody Keytruda.
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.